BRPI0813645A2 - Métodos para modificar anticorpos, e anticorpos modificados com propriedades funcionais aperfeiçoadas - Google Patents

Métodos para modificar anticorpos, e anticorpos modificados com propriedades funcionais aperfeiçoadas

Info

Publication number
BRPI0813645A2
BRPI0813645A2 BRPI0813645-9A2A BRPI0813645A BRPI0813645A2 BR PI0813645 A2 BRPI0813645 A2 BR PI0813645A2 BR PI0813645 A BRPI0813645 A BR PI0813645A BR PI0813645 A2 BRPI0813645 A2 BR PI0813645A2
Authority
BR
Brazil
Prior art keywords
antibodies
methods
functional properties
modifying
perfect functional
Prior art date
Application number
BRPI0813645-9A2A
Other languages
English (en)
Inventor
David Urech
Leonardo Borras
Original Assignee
Esbatech Alcon Biomed Res Unit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39820887&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0813645(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Esbatech Alcon Biomed Res Unit filed Critical Esbatech Alcon Biomed Res Unit
Publication of BRPI0813645A2 publication Critical patent/BRPI0813645A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0813645-9A2A 2007-06-25 2008-06-25 Métodos para modificar anticorpos, e anticorpos modificados com propriedades funcionais aperfeiçoadas BRPI0813645A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93711207P 2007-06-25 2007-06-25
US6905608P 2008-03-12 2008-03-12
PCT/CH2008/000285 WO2009000099A2 (en) 2007-06-25 2008-06-25 Methods of modifying antibodies, and modified antibodies with improved functional properties

Publications (1)

Publication Number Publication Date
BRPI0813645A2 true BRPI0813645A2 (pt) 2014-12-30

Family

ID=39820887

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0813645-9A2A BRPI0813645A2 (pt) 2007-06-25 2008-06-25 Métodos para modificar anticorpos, e anticorpos modificados com propriedades funcionais aperfeiçoadas

Country Status (20)

Country Link
US (2) US20090074780A1 (pt)
EP (1) EP2158315B1 (pt)
JP (5) JP5611820B2 (pt)
KR (1) KR101573086B1 (pt)
CN (6) CN111253484A (pt)
AU (1) AU2008267734B9 (pt)
BR (1) BRPI0813645A2 (pt)
CA (1) CA2689941C (pt)
DK (1) DK2158315T3 (pt)
ES (1) ES2566737T3 (pt)
HR (1) HRP20160730T1 (pt)
HU (1) HUE027507T2 (pt)
IL (1) IL202360A (pt)
MX (1) MX2009013328A (pt)
NZ (2) NZ581468A (pt)
PL (1) PL2158315T3 (pt)
RU (3) RU2540150C2 (pt)
SI (1) SI2158315T1 (pt)
WO (1) WO2009000099A2 (pt)
ZA (1) ZA200908384B (pt)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4793360A2 (en) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
CN101222758B (zh) 2007-01-08 2011-10-26 中兴通讯股份有限公司 一种在高速分组数据网传递1x寻呼被拒绝的方法
NZ579594A (en) 2007-03-12 2012-03-30 Esbatech Alcon Biomed Res Unit Sequence based engineering and optimization of single chain antibodies
CN101688200B (zh) 2007-06-25 2012-08-08 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 单链抗体的基于序列的改造和优化
NZ581468A (en) * 2007-06-25 2012-09-28 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies, and modified antibodies with improved functional properties
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
PL2307455T3 (pl) 2008-06-25 2017-09-29 Esbatech, An Alcon Biomedical Research Unit Llc Optymalizacja rozpuszczalności cząsteczek immunowiążących
KR20180005753A (ko) 2008-06-25 2018-01-16 에스바테크 - 어 노바티스 컴파니 엘엘씨 Vegf를 억제하는 안정하고 가용성인 항체
PL2307458T3 (pl) 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
RU2653753C1 (ru) 2008-06-25 2018-05-14 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи СТАБИЛЬНЫЕ И РАСТВОРИМЫЕ АНТИТЕЛА, ИНГИБИРУЮЩИЕ TNFα
RU2582244C2 (ru) 2008-06-30 2016-04-20 ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи Функционализированные полипептиды
JP2012521197A (ja) 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド 担体免疫グロブリンおよびその使用
US8399625B1 (en) 2009-06-25 2013-03-19 ESBATech, an Alcon Biomedical Research Unit, LLC Acceptor framework for CDR grafting
AU2010321832B2 (en) 2009-11-20 2014-08-14 Amgen Inc. Anti-Orai1 antigen binding proteins and uses thereof
CA2885176C (en) 2010-09-22 2018-10-23 Amgen Inc. Carrier immunoglobulins and uses thereof
US8962804B2 (en) 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
CA2814040C (en) 2010-10-08 2021-03-23 Joshua Michael Donaldson A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
AU2013203189B2 (en) * 2010-10-22 2014-12-11 Novartis Ag Stable and soluble antibodies
UY33679A (es) * 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
AU2016277637B2 (en) * 2010-10-22 2018-11-08 Novartis Ag Stable and soluble antibodies
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
KR102276792B1 (ko) * 2011-10-10 2021-07-15 시티 오브 호프 메디토프와 메디토프-결합 항체 및 이들의 용도
AU2012325232B2 (en) * 2011-10-20 2017-08-31 Esbatech - A Novartis Company Llc Stable multiple antigen-binding antibody
US9428553B2 (en) 2012-02-10 2016-08-30 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
CA2865158C (en) 2012-02-24 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting disappearance of antigen via fc.gamma.riib
EP3553089A1 (en) * 2012-05-10 2019-10-16 Bioatla, LLC Multi-specific monoclonal antibodies
TWI855488B (zh) 2012-08-24 2024-09-11 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスFcγRII特異的Fc抗体
SG11201508170TA (en) 2013-04-02 2015-11-27 Chugai Pharmaceutical Co Ltd Fc REGION VARIANT
HK1218549A1 (zh) 2013-06-26 2017-02-24 Numab Therapeutics AG 新型抗体框架
CN104341501B (zh) * 2013-07-29 2019-08-30 上海睿智化学研究有限公司 抗IL-1β人源化单克隆抗体及其制备方法和应用
IL318433A (en) 2014-05-16 2025-03-01 Ablynx Nv Improved immunoglobulin variable complexes
LT3248986T (lt) * 2014-05-16 2022-03-25 Ablynx Nv Imunoglobulino kintami domenai
UY36302A (es) 2014-09-15 2016-04-29 Amgen Inc Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp/receptor pac1 y usos de las mismas
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
CN114773469B (zh) 2015-02-05 2025-12-19 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il-8-结合抗体及其应用
JP6932700B2 (ja) 2015-09-15 2021-09-08 アムジエン・インコーポレーテツド 4価の二重特異性抗原結合タンパク質及び4価の四重特異性抗原結合タンパク質、ならびにそれらの使用
US10822408B2 (en) 2015-12-15 2020-11-03 Amgen Inc. PACAP antibodies and uses thereof
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE
EP4086285A1 (en) 2016-02-25 2022-11-09 Cell Medica Switzerland AG Binding members to pd-l1
CN116271014A (zh) 2016-08-05 2023-06-23 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
AU2017356317A1 (en) 2016-11-14 2019-05-30 Amgen Inc. Bispecific or biparatopic antigen binding proteins and uses thereof
KR20240148849A (ko) * 2017-03-20 2024-10-11 캔서 테라퓨틱스 래버러토리즈 인코포레이티드 암 치료법에서 괴사를 표적화하기 위한 인간화 항-핵 항체
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
JP7339262B2 (ja) 2018-01-12 2023-09-05 アムジェン インコーポレイテッド Pac1抗体及びその使用
TWI827585B (zh) 2018-03-15 2024-01-01 日商中外製藥股份有限公司 對茲卡病毒具有交叉反應性的抗登革病毒抗體及其使用方法
CN112513081A (zh) 2018-06-14 2021-03-16 生物蛋白有限公司 多重特异性抗体构建体
SG11202107129QA (en) * 2019-01-03 2021-07-29 Amgen Inc Engineering monoclonal antibodies to improve stability and production titer
AU2020283890A1 (en) 2019-05-30 2021-12-16 Amgen Inc. Engineering the hinge region to drive antibody dimerization
WO2020264384A1 (en) 2019-06-28 2020-12-30 Amgen Inc. Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
EP3767628B1 (de) * 2019-07-18 2024-03-27 Bayer Aktiengesellschaft Selektion von antikörpern / antikörperfragmenten
CA3160482A1 (en) 2019-11-08 2021-05-14 Amgen Inc. Engineering charge pair mutations for pairing of hetero-igg molecules
US20230047631A1 (en) 2019-11-19 2023-02-16 Amgen Inc. Novel multispecific antibody format
IL293640A (en) 2019-12-20 2022-08-01 Amgen Inc CD40 antagonistic mesothelin-targeted multispecific antibody constructs for the treatment of solid tumors
EP4200338A1 (en) 2020-08-20 2023-06-28 Amgen Inc. Antigen binding proteins with non-canonical disulfide in fab region
EP4225786A2 (en) 2020-10-07 2023-08-16 Amgen Inc. Rational selection of building blocks for the assembly of multispecific antibodies
EP4244246A1 (en) 2020-11-10 2023-09-20 Amgen Inc. Novel linkers of multispecific antigen binding domains
US20220259296A1 (en) 2021-02-12 2022-08-18 Boehringer Ingelheim International Gmbh Complement c3 antigen binding proteins
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
EP4304726A1 (en) 2021-03-09 2024-01-17 CDR-Life AG Mage-a4 peptide-mhc antigen binding proteins
US20240182600A1 (en) 2021-04-20 2024-06-06 Amgen Inc. Balanced Charge Distribution in Electrostatic Steering of Chain Pairing in Multi-specific and Monovalent IgG Molecule Assembly
EP4183800A1 (en) 2021-11-19 2023-05-24 Medizinische Hochschule Hannover Novel sars-cov-2 neutralizing antibodies
CA3240046A1 (en) 2021-12-14 2023-06-22 Cdr-Life Ag Dual mhc-targeting t cell engager
PE20250390A1 (es) 2021-12-22 2025-02-11 Boehringer Ingelheim Int Anticuerpos anti-c3 y fragmentos de union al antigeno de estos y sus usos para tratar enfermedades oftalmicas u oculares
WO2024038095A1 (en) 2022-08-16 2024-02-22 Iome Bio NOVEL ANTI-RGMb ANTIBODIES
EP4587046A1 (en) 2022-09-14 2025-07-23 CDR-Life AG Mage-a4 peptide dual t cell engagers
JP2026522281A (ja) * 2023-06-05 2026-07-07 サノフイ 機械学習モデルを使用した単一可変ドメインの特性の予測
WO2025210181A1 (en) 2024-04-04 2025-10-09 Cdr-Life Ag Antigen binding proteins targeting an hla-restricted kk-lc-1 peptide
WO2025215160A1 (en) 2024-04-11 2025-10-16 Cdr-Life Ag Antigen binding proteins targeting an hla-restricted prame peptide

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1197800A (en) * 1983-05-02 1985-12-10 William O. Weigle Immune modulator peptides
AU658396B2 (en) 1991-03-06 1995-04-13 Merck Patent Gesellschaft Mit Beschrankter Haftung Humanized and chimeric monoclonal antibodies
DE69233482T2 (de) * 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
ATE139900T1 (de) * 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
WO1994025591A1 (en) * 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
US6740734B1 (en) 1994-01-14 2004-05-25 Biovitrum Ab Bacterial receptor structures
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
ATE239041T1 (de) 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US5942602A (en) * 1997-02-13 1999-08-24 Schering Aktiengessellschaft Growth factor receptor antibodies
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
JP3614866B2 (ja) * 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ,インコーポレイティド 人工抗体ポリペプチド
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
PT1974747E (pt) 1998-08-11 2012-09-05 Biogen Idec Inc Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20
WO2000032634A1 (en) 1998-12-01 2000-06-08 Protein Design Labs, Inc. Humanized antibodies to gamma-interferon
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
SE9901379D0 (sv) 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
US6602977B1 (en) 1999-04-19 2003-08-05 Biovitrum Ab Receptor structures
EP1479694B1 (en) 1999-12-28 2016-10-26 ESBATech, an Alcon Biomedical Research Unit LLC Intrabodies ScFv with defined framework that is stable in a reducing environment
EP2287190B1 (en) * 2000-05-10 2014-12-17 Mayo Foundation For Medical Education And Research Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
NZ525793A (en) 2000-10-13 2008-04-30 Biogen Idec Inc Humanized anti-LT-beta-R antibodies
GB0029360D0 (en) 2000-12-01 2001-01-17 Univ Nottingham Humanised antibodies and uses thereof
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
JP4369662B2 (ja) 2001-04-26 2009-11-25 アビディア インコーポレイテッド 単量体ドメインのコンビナトリアルライブラリー
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
CA2447935A1 (en) * 2001-06-04 2002-12-12 Curagen Corporation Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
JP4355571B2 (ja) * 2001-07-19 2009-11-04 ウニベルジテート チューリッヒ ヒト可変ドメインの改変
AR037756A1 (es) * 2001-12-17 2004-12-01 Bayer Corp Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma.
CA2471938A1 (en) 2001-12-28 2003-07-17 Kyowa Hakko Kogyo Co., Ltd. Agent for treating arthritis
US6905608B2 (en) 2002-01-22 2005-06-14 Exergy Technologies Corporation Advanced electrodeionization for fluid recycling
CN102093477B (zh) * 2002-05-22 2014-02-26 艾斯巴技术-诺华有限责任公司 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法
US7696320B2 (en) * 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
CN1678625A (zh) 2002-07-01 2005-10-05 比奥根艾迪克Ma公司 人源化抗淋巴毒素β受体的抗体
KR101115797B1 (ko) 2002-08-01 2012-07-27 이뮤노메딕스, 인코오포레이티드 알파 태아 단백질 Immu31 항체 및 융합단백질, 및이들의 이용 방법
HUE035898T2 (en) * 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
WO2004065417A2 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
CN1798767B (zh) * 2003-04-10 2011-02-16 晶面生物技术公司 通过诱变来改变抗体对FcRn的结合亲和力或血清半衰期
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
CN1863556B (zh) 2003-06-19 2012-05-16 吉宁特有限公司 用于治疗凝血相关紊乱的组合物和方法
EP1644416A4 (en) 2003-06-30 2007-08-29 Centocor Inc ANTI-TARGET AND GENETICALLY MODIFIED IMMUNOGLOBULIN-DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
US7691970B2 (en) 2003-08-25 2010-04-06 Pieris Ag Muteins of a bilin-binding protein with affinity for a given target
HUE038955T2 (hu) 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
WO2005051998A2 (en) * 2003-11-28 2005-06-09 Astrazeneca Ab Antibodies binding to a c-terminal fragment of apolipoprotein e
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
US8039588B2 (en) 2004-05-21 2011-10-18 The Uab Research Foundation Variable lymphocyte receptors
PL2314621T3 (pl) 2004-05-27 2014-08-29 Crucell Holland Bv Cząsteczki wiążące zdolne do neutralizowania wirusa wścieklizny i ich zastosowania
GB0416651D0 (en) * 2004-07-26 2004-08-25 Proteo Target Aps Polypeptide
US7462697B2 (en) * 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
CN101171034B (zh) 2005-03-03 2014-06-18 免疫医疗公司 人源化l243抗体
PT2360255E (pt) 2005-03-25 2015-04-08 Nat Res Council Canada Método para isolamento de polipéptidos solúveis
CN103665168A (zh) 2005-06-03 2014-03-26 持田制药株式会社 抗cd14抗体融合蛋白质
EP1891110A2 (en) * 2005-06-07 2008-02-27 Esbatech AG STABLE AND SOLUBLE ANTIBODIES INHIBITING TNF-alpha
CA2614076A1 (en) 2005-07-05 2007-01-11 Glaxo Group Limited Humanised antibodies specific for nogo-a and pharmaceutical uses thereof
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
AU2006290433B2 (en) 2005-08-26 2012-06-07 Roche Glycart Ag Modified antigen binding molecules with altered cell signaling activity
WO2007062037A2 (en) * 2005-11-21 2007-05-31 Laboratoires Serono Sa Compositions and methods of producing hybrid antigen binding molecules and uses thereof
WO2007060411A1 (en) 2005-11-24 2007-05-31 Ucb Pharma S.A. Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r
PL1963368T6 (pl) * 2005-12-13 2021-02-08 Eli Lilly And Company Przeciwciała anty-IL-17
US20070218116A1 (en) * 2006-03-14 2007-09-20 Schwendener Reto A Compositions and methods for the treatment of tumors and tumor metastases
JP5144499B2 (ja) 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
ES2603399T3 (es) 2006-07-10 2017-02-27 Esbatech, An Alcon Biomedical Research Unit Llc Anticuerpos scFv que atraviesan capas epiteliales y/o endoteliales
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン.ヴェー. Il−6媒介性シグナル伝達に関連する疾患及び障害の治療のための、il−6rに指向性を有するアミノ酸配列及びこれを含むポリペプチド
CN101210241A (zh) * 2006-12-27 2008-07-02 陕西超英生物科技有限公司 一种噬菌体基因工程抗体库基因组装的方法
NZ579594A (en) 2007-03-12 2012-03-30 Esbatech Alcon Biomed Res Unit Sequence based engineering and optimization of single chain antibodies
NZ581468A (en) 2007-06-25 2012-09-28 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies, and modified antibodies with improved functional properties
CN101688200B (zh) 2007-06-25 2012-08-08 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 单链抗体的基于序列的改造和优化
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr

Also Published As

Publication number Publication date
JP2019141091A (ja) 2019-08-29
RU2019118109A (ru) 2020-12-11
CN103435696B (zh) 2016-10-12
EP2158315A2 (en) 2010-03-03
CN111253484A (zh) 2020-06-09
US20190002551A1 (en) 2019-01-03
JP2017186338A (ja) 2017-10-12
NZ581468A (en) 2012-09-28
RU2014142680A (ru) 2016-05-20
HUE027507T2 (en) 2016-10-28
AU2008267734A1 (en) 2008-12-31
EP2158315B1 (en) 2016-03-23
CN101849001B (zh) 2014-07-16
DK2158315T3 (en) 2016-06-06
HRP20160730T1 (hr) 2016-07-15
CN106366192B (zh) 2020-03-27
AU2008267734B9 (en) 2014-09-11
CN102838673A (zh) 2012-12-26
CN103435696A (zh) 2013-12-11
RU2010102065A (ru) 2011-07-27
WO2009000099A3 (en) 2009-04-09
AU2008267734B2 (en) 2014-07-24
ZA200908384B (en) 2011-02-23
JP6129797B2 (ja) 2017-05-17
MX2009013328A (es) 2010-06-02
JP2015007104A (ja) 2015-01-15
CN101849001A (zh) 2010-09-29
RU2014142680A3 (pt) 2018-05-28
CN102838673B (zh) 2016-05-11
KR101573086B1 (ko) 2015-11-30
KR20100028575A (ko) 2010-03-12
IL202360A (en) 2015-07-30
CN105017427A (zh) 2015-11-04
NZ601946A (en) 2013-12-20
JP5611820B2 (ja) 2014-10-22
US20090074780A1 (en) 2009-03-19
CA2689941A1 (en) 2008-12-31
CA2689941C (en) 2019-10-29
WO2009000099A2 (en) 2008-12-31
PL2158315T3 (pl) 2016-10-31
JP2021119782A (ja) 2021-08-19
SI2158315T1 (sl) 2016-05-31
ES2566737T3 (es) 2016-04-15
HK1137483A1 (zh) 2010-07-30
RU2540150C2 (ru) 2015-02-10
JP2010531145A (ja) 2010-09-24
IL202360A0 (en) 2011-08-01
CN106366192A (zh) 2017-02-01

Similar Documents

Publication Publication Date Title
CY2019004I2 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BRPI0812446A2 (pt) Métodos para aperfeiçoamento de propriedades de proteína múltiplas
LTPA2017019I1 (lt) Žmogaus antikūnai, pasižymintys dideliu giminingumu PCSK9
IL202360A0 (en) Methods of modifying antibodies, and modified antibodies with improved functional properties
BRPI0807991A2 (pt) Anticorpos anti-il-23r elaborados.
BRPI0918122A2 (pt) molécula de diaboy, diaboy, e mólecula dart
PL3059246T3 (pl) Zmodyfikowany region stały przeciwciała
BRPI0814467A2 (pt) Método, e, biocombustível
PT2427212T (pt) Anticorpos anti-cd100 e métodos para utilização dos mesmos
BRPI0818572A2 (pt) Depósito de material, e, dispositivo elétrico
IL213116B (en) Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan
CR10705A (es) Anticuerpos para linfotoxina-alfa
BRPI0809573A2 (pt) composição, e, método
BRPI0715917A2 (pt) Anticorpos para il-17a
BRPI0807755A2 (pt) Sementes revestidas e métodos para fabricação de sementes revestidas.
BRPI0923159A2 (pt) gene de delta-endotoxina axmi-150 e métodos para sua utilização.
BRPI0916787A2 (pt) artigo, e, método para fabricar um artigo
BRPI0812744A2 (pt) Métodos para melhoramento molecular direcionado por sequência
PL2354161T3 (pl) Przeciwciało anty -NR10 i jego zastosowanie
BRPI0819085A2 (pt) Sistema para uso com produção de hidrocarbonetos, e, método associado com produção de hidrocarbonetos
BRPI0820298A2 (pt) anticorpos anti-vegf composições e métodos
BRPI0918642A2 (pt) coque e método para fabricação do mesmo.
BRPI0813216A2 (pt) Inibidores de proteínas cinases e métodos para usá-los.
DK2046831T3 (da) Hidtil ukendte, multivalente immunoglobuliner
BRPI0919575A2 (pt) método, e, composição

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2625 DE 27-04-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.